STOCK TITAN

Athira Pharma Inc - ATHA STOCK NEWS

Welcome to our dedicated news page for Athira Pharma (Ticker: ATHA), a resource for investors and traders seeking the latest updates and insights on Athira Pharma.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Athira Pharma's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Athira Pharma's position in the market.

Rhea-AI Summary
Athira Pharma, Inc. (ATHA) to Highlight Preclinical Data for Potential ALS Treatment Candidate ATH-1105 at MNDA Symposium
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.88%
Tags
conferences
-
Rhea-AI Summary
Athira Pharma, Inc. (NASDAQ: ATHA) presented new preclinical data at the Society for Neuroscience Annual Meeting 2023 supporting the potential therapeutic benefit of fosgonimeton for the treatment of Alzheimer’s disease (AD) and other neurodegenerative diseases. Fosgonimeton is a potentially first-in-class, small-molecule, brain-penetrant positive modulator of the neurotrophic hepatocyte growth factor (HGF) system. The data demonstrated consistent neuroprotective effects of fosgonimeton, including protection of neurons from toxic amyloid-beta (Aβ) and decreased tau phosphorylation. Fosgonimeton also improved cognitive performance and reduced hippocampal neuron loss in an Aβ model of AD. The presentations are available on the company’s website at www.athira.com.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.61%
Tags
-
Rhea-AI Summary
Athira Pharma, Inc. (NASDAQ: ATHA) reported clinical and preclinical findings supporting small molecule therapeutic candidates targeting the neurotrophic HGF system for neurodegenerative diseases. Phase 2/3 LIFT-AD trial of fosgonimeton in Alzheimer’s patients to complete enrollment by Q1 2024 with topline data in H2 2024. The company maintains a strong balance sheet to support clinical development pipeline.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.47%
Tags
Rhea-AI Summary
Athira Pharma, Inc. (NASDAQ: ATHA) announces participation at Jefferies London Healthcare Conference. The late clinical-stage biopharmaceutical company will hold a Fireside Chat on November 16, 2023, to discuss small molecule development for neuronal health and neurodegeneration. A live webcast and archived replay will be available on the Athira website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.66%
Tags
conferences
-
Rhea-AI Summary
ATH-1105 shows neuroprotective effects in preclinical models of ALS, according to new data presented by Athira Pharma
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5%
Tags
-
Rhea-AI Summary
Athira Pharma to participate in upcoming investor conferences in October
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.04%
Tags
conferences
Rhea-AI Summary
Athira Pharma to participate in panel presentation at 2023 Cantor Fitzgerald Global Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.62%
Tags
conferences
-
Rhea-AI Summary
Athira Pharma, Inc. (NASDAQ: ATHA) reported financial results for Q2 2023, highlighting advancements in their pipeline, including the Phase 2/3 LIFT-AD trial for Alzheimer's disease treatment. They also appointed Andrew Gengos as CFO and CBO, and maintain a strong balance sheet.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.26%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.47%
Tags
conferences
Athira Pharma Inc

Nasdaq:ATHA

ATHA Rankings

ATHA Stock Data

80.87M
26.94M
2.19%
62.85%
2.63%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United States
Bothell

About ATHA

m3 biotechnology is an innovative therapeutics company that has a novel platform of disease-modifying regenerative small molecules, particularly relevant to neurodegenerative diseases. the lead compound modifies growth-factor systems, where the activation is expected to stop disease progression and even restore lost function. the company’s research has been funded by the alzheimer’s drug discovery foundation, washington’s life sciences discovery fund, w fund, wrf capital, dolby family ventures and other private investors. where current and emerging therapies are focused primarily on disease symptoms and improving the quality of life of patients suffering from disease, m3 differentiates itself from the competition by addressing the neurodegenerative process, providing a cost-effective solution and feasible delivery mechanism. our strategy is to leverage our patented and proprietary technologies to develop small molecule modulators with a primary focus on altering the course of alzheimer